Should I get a comprehensive genomic panel for Merkel Cell Carcinoma

Genomic Testing for Merkel Cell Carcinoma: What You Should Know

This is an important question, and the answer depends on several factors specific to your situation. Let me explain what the current medical guidelines recommend and what questions to discuss with your care team.

What the Guidelines Say

According to the NCCN Guidelines for Merkel Cell Carcinoma (Version 2.2026), genomic testing considerations include:

Tissue-Informed Testing:

• If your initial diagnosis was made with a core biopsy (a small needle sample), the NCCN Guidelines recommend collecting additional tumor tissue before starting immunotherapy or radiation therapy. This tissue can be used for circulating tumor DNA (ctDNA) testing, which is a blood-based test that can track your disease.

Virus Status Testing:

• Testing for Merkel cell polyomavirus (MCPyV) antibodies is recommended as part of your initial workup. According to NCCN Guidelines, this matters because:
  • Patients who test seronegative (no antibodies) have higher recurrence risk
  • Patients who test seropositive (have antibodies) may show rising titers as an early sign of recurrence
  • Baseline testing should happen within 3 months of treatment

Why Genomic Information Matters for MCC

Research cited in the NCCN Guidelines shows that:

• MCPyV-positive vs. MCPyV-negative MCC are distinct disease subtypes with different characteristics and potentially different treatment responses
• Tumor mutation burden (the total number of mutations in your cancer) may influence immunotherapy eligibility
• Circulating tumor DNA (ctDNA) testing can detect recurrence earlier than imaging and is increasingly used for surveillance

The Clinical Decision-Making Framework

Doctors typically consider comprehensive genomic testing when:

1. You're planning immunotherapy - Understanding your tumor's genetic profile helps predict response to checkpoint inhibitors (like avelumab or pembrolizumab)
2. You have advanced or recurrent disease - More information helps identify treatment options
3. Standard treatments aren't working - Genomic data may reveal alternative pathways to target
4. You're considering clinical trials - Many trials require specific genetic information

Questions to Ask Your Oncology Team

Since comprehensive genomic testing decisions are highly individualized, here are specific questions to discuss:

1. "Based on my stage and treatment plan, do you recommend comprehensive genomic testing, or is MCPyV antibody testing sufficient for now?"

2. "If I do get genomic testing, will the results change my treatment recommendations?" (This helps determine if testing is actionable for your specific case)

3. "Should I have tissue collected for circulating tumor DNA (ctDNA) testing before I start treatment?" (NCCN Guidelines recommend this if you haven't had adequate tissue sampling)

4. "Are there clinical trials I might be eligible for that would require genomic testing?"

5. "How often should I be monitored with ctDNA testing if I proceed with it?" (NCCN Guidelines suggest every 3 months for surveillance)

6. "What is the cost, and will my insurance cover it?" (This is practical but important)

Important Context

According to NCCN Guidelines, approximately 20% of MCC patients under age 50 have mutations in known cancer-associated genes that may be heritable. If you're in this age group, your doctor may recommend genetic counseling to evaluate for germline (inherited) mutations.

The Bottom Line

Comprehensive genomic testing can be valuable for MCC, but it's not automatically recommended for everyone. The key is whether the results would actually change your treatment decisions. Your oncologist can best determine if testing is appropriate for your specific stage, treatment plan, and clinical situation.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.